Clinical trial / 2004
Oral aloe vera gel increased clinical response in mildly to moderately active ulcerative colitis.
Forty-four outpatients with active ulcerative colitis were randomized to receive 100 mL oral aloe vera gel or placebo twice daily for four weeks. Clinical response occurred in 47% (14 of 30) of patients receiving aloe vera compared to 14% (2 of 14) given placebo (p < 0.05; odds ratio 5.3, 95% CI 1.0-27). Aloe vera significantly reduced clinical colitis activity (p = 0.01) and histological scores (p = 0.03), while sigmoidoscopic scores and adverse events did not differ between groups.
- Study type
- Randomized controlled trial
- Who was studied
- 44 hospital outpatients with active ulcerative colitis
- What was measured
- Clinical, sigmoidoscopic, and histological remission
THE PAPER
Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis.
Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS. Aliment Pharmacol Ther, 2004.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.